QIAGEN
Financial Report 2017
- Solid 2017 performance as QIAGEN moving ahead on a new growth trajectory
- Group adjusted net sales rise 6% at constant exchange rates (CER) to $1.42 billion
- Adjusted operating income grows 14% to $371.5 million
- Adjusted diluted EPS of $1.27 per share vs. $1.11 in 2016
- Free cash flow of $196.7 million, impacted by $89 million of restructuring and litigation settlement payments
- Sustaining growth trajectory toward 2020 goals with Sample to Insight portfolio